Despite improvements in glycemic and blood pressure control in patients with type 1 diabetes, diabetic nephropathy remains the most common cause of chronic kidney disease worldwide. A major challenge in preventing diabetic nephropathy is the inability to identify high-risk patients at an early stage, emphasizing the importance of discovering new therapeutic targets and implementation of clinical trials to reduce diabetic nephropathy risk.
INTRODUCTION
Diabetic nephropathy is the leading cause of mortality in type 1 diabetes (T1D) [1] [2] [3] . Microalbuminuria, generally recognized as the earliest clinical phenotype of diabetic nephropathy, has a cumulative lifetime incidence of approximately 50% in T1D and develops at a rate of around 2-3% annually [4 && ]. A quarter of T1D patients with diabetic nephropathy progress to end-stage renal disease (ESRD) [5] . In fact, the 2011 US Renal Data System showed that diabetic nephropathy accounted for 44.5% of all cases of ESRD in the USA in 2009, making it the most common cause of ESRD [6] . Diabetic nephropathy is also an important risk factor for coronary artery disease (CAD) [7,8,9 && ] and overall mortality [7, 10] . The natural history of diabetic nephropathy is characterized by a long silent period without overt clinical signs and symptoms of nephropathy. This is further complicated by undertreatment in adolescents with T1D, as recently shown by data from the T1D Exchange registry that reported that only a third of patients less than 20 years with a clinical diagnosis of microalbuminuria received ACE inhibitors (ACEi)/angiotensin-receptor blockers (ARB) [11 refractory to therapeutic strategies including improved blood pressure and glycemic control [12, 13] . Current therapeutic strategies may slow but do not prevent the progression of diabetic nephropathy [4 && ,14] . Earlier, identification of GFR decline would allow interventions to decrease the rate of GFR loss and prolong the time to develop ESRD ( Fig. 1) [15] .
Although there is strong evidence showing the benefit of glycemic and blood pressure control in preventing microvascular complications in T1D [1, 16, 17] , optimal control does not abolish the risk. In fact, diabetic nephropathy outcomes have not changed significantly and continue to be a major concern for endocrinologists and nephrologists caring for patients with T1D [1,2]. Managing diabetic nephropathy in patients with T1D has been further complicated by disappointing results of reninangiotensin-aldosterone system (RAAS) inhibitor trials, including the failure of primary prevention studies [The Renin Angiotensin System Study (RASS)] [18] and the demonstration of harm with dual RAAS blockade [19 && ]. Furthermore, once promising renoprotective strategies for diabetic nephropathy including protein kinase C-b antagonists, selective endothelin receptor-A antagonists, and the nuclear factor-like 2 modulator bardoxolone have resulted in disappointing clinical trial results [20] [21] [22] .
Therefore, it is important to identify novel and modifiable risk factors that contribute to the development and progression of early diabetic nephropathy [23] . Understanding these risk factors may enable us to identify patients at high risk of early diabetic nephropathy and intervene at a time when the renal lesions might be responsive to therapy. Accordingly, in this review, we examine the current evidence addressing novel mediators and therapeutic targets in T1D to prevent diabetic nephropathy (Table 1) [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] .
EARLY DIABETIC NEPHROPATHY
In the conventional paradigm of diabetic nephropathy, progressive pathologic changes develop over a long silent period without evidence of proteinuria, hypertension, or impaired GFR [35] . In this paradigm, during the clinically silent phase, a significant proportion of patients exhibit renal hyperfiltration secondary to elevated intraglomerular pressure resulting in a glomerular injury, followed by microalbuminuria and progressive GFR decline, eventually resulting in ESRD [36] . Renal hyperfiltration is the earliest hemodynamic abnormality seen in diabetes, and has been linked with an increased risk of diabetic nephropathy in many, but not all, studies, reflected by microalbuminuria and declining GFR [36] . In addition to controversy around hyperfiltration in the pathogenesis of diabetic nephropathy, hyperfiltration remains difficult to detect clinically with current GFR estimating equations. The appearance of microalbuminuria is usually the earliest clinical sign of diabetic nephropathy, but the paradigm of early diabetic nephropathy in T1D has been further questioned over the past few years after the demonstration that microalbuminuria does not necessarily imply progressive nephropathy, and may in fact regress to normoalbuminuria (Fig. 2 ) [37, 38] . Early progressive renal decline, defined as an annual estimated GFR (eGFR) decline greater than 3.3% [39 && ] or 3 ml/min/1.73 m 2 [40, 41] , has been shown to occur prior to the onset of microalbuminuria [39 && ] and thought to be more predictive of progression to impaired renal function and eventual ESRD than microalbuminuria [39 && ,42]. Unfortunately, current understanding of determinants implicated in early GFR loss is limited [42] . Recently identified modifiable biomarkers, including serum uric acid (SUA) [24,25 && ] and insulin sensitivity [25 && ], may provide insight into the design of more effective programs for preventing diabetic nephropathy in T1D, reflected either by microalbuminuria and/or early GFR decline.
KEY POINTS
Diabetic nephropathy remains the most common cause of chronic kidney disease worldwide.
There is a need for improved methods of detecting early diabetic nephropathy.
Novel targets to prevent diabetic nephropathy include serum uric acid, insulin sensitivity, vasopressin, and SGLT-2. 
CURRENT METHODS OF IDENTIFYING EARLY DIABETIC NEPHROLOGY
The American Diabetes Association and the International Society of Nephrology recommend annual screening for albuminuria and also measurement of estimated eGFR to identify and monitor diabetic nephropathy [43, 44] . Microalbuminuria is defined as albumin excretion rate at least 20 mg/min or albumin-creatinine ratio at least 30 mg/g, and both have been shown to be associated with the expansion of the glomerular basement membrane in T1D [45] . The most state-of-the-art equations to estimate GFR for adults are the three recently published Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI creatinine, CKD-EPI cystatin C, and CKD-EPI creatinine and cystatin C [46] , and for children and adolescents, CKiD creatinine and cystatin C equations [47] .
However, when eGFR is more than 90 ml/min/ 1.73 m 2 , concordance between CKD-EPI cystatin C eGFR and CKD-EPI creatinine eGFR has been reported to be as low as 56% [48 && ,49]. These results echo the discordance between eGFR by CKD-EPI creatinine and CKD-EPI cystatin C reported by Inker et al. [46] in patients with normal-to-high eGFR.
Overall, CKD-EPI cystatin C eGFR is considered to be less biased by age and weight compared with creatinine-based measurements, and correlates more closely with direct measures of GFR over a wide spectrum of plasma glucose levels compared with creatinine-based measures in experimental studies [41, 50] . These observations suggest that cystatin C more accurately reflects measured GFR in patients with T1D, favoring its use as an estimate of GFR in this population. Moreover, GFR estimated by cystatin C seems to better predict microvascular and ]. Cystatin C more accurately detected rapid GFR decline than creatinine-based measurements in T1D subjects with normal renal function [52] . Rapid GFR decline estimated by cystatin C is also associated with a higher risk for cardiovascular complications and mortality than creatinine-based GFR estimation [40,48 && ]. Furthermore, Skupien et al. [53 & ] demonstrated that GFR staging with eGFR CYSTATIN C is superior for predicting ESRD and mortality compared with eGFR BOTH , which might suggest that serum creatinine counters the predictive effect of serum cystatin C. Finally, Shlipak et al. [54] demonstrated that the use of cystatin C compared with creatinine strengthens the association between eGFR and risk of death and ESRD in 11 diverse general-population studies.
Despite the possible superiority of cystatin C versus creatinine, estimates of GFR by both serum creatinine and cystatin C, such as measurements of urinary albumin excretion, remain imperfect [9 && ,55,56] . The CKD-EPI eGFR equation has not been validated in people with eGFR higher than 80 ml/min/1.73 m 2 , and it is associated with greater variability when eGFR higher than 60 ml/min/ 1.73ïm 2 [46] . However, by the time eGFR is 60 ml/ min/1.73 m 2 or less, almost half of the renal function has been lost [57] (Fig. 3) [58] .
Improved methods to easily and accurately measure GFR and changes in renal function in the normal and hyperfiltration range are therefore needed. Gold-standard measures of GFR with iothalamate, iohexol, or inulin clearance in people with T1D are impractical and not routinely performed in clinical practice. Recently, a practical method of measuring GFR by iohexol clearance using dried capillary blood spots has been developed in nondiabetic patients [59, 60] , which is ideally suited for people with T1D [Maahs, D., Bushman, L., Kerr, B., Ellis, S., McFann, K., Pyle, L., Bouffard, A. Nguyen, N., Anderson, P. A Practical Method to Measure GFR in people with type 1 diabetes. Journal of Diabetes and Its Complications 2014 (in press)] in whom early detection of diabetic nephropathy is imperative to prevent early morbidity and mortality [2,61], which may hopefully allow the early identification of patients at increased risk of early diabetic nephropathy. Simultaneous hyperglycemia has an effect on renal hemodynamics and a difference of 4-6 mmol/l versus 9-11 mmol/l is associated with a 15-18 ml/min/1.73 m 2 difference in GFR measured by inulin [50] . Furthermore, we have demonstrated that simultaneous blood glucose has an independent positive effect on eGFR by cystatin C, which could bring bias in the accurate detection of early diabetic nephropathy [49, 62] . Accounting for ambient blood glucose could improve intraindividual precision in GFR change over time in people with T1D.
Another promising method of identifying early diabetic nephropathy is through the use of urinary proteomic techniques. Because many urinary proteomic markers remain stable long enough to perform reliable polypeptide analysis, the emerging field of proteomics has given some recent insight into the development of practical and noninvasive novel biomarkers [63] . The association between urinary proteomics and diabetic nephropathy is well recognized [33, [64] [65] [66] [67] . Both acute hyperglycemia and renal hyperfiltration are associated with increased urinary excretion of inflammatory cytokines/chemokines (e.g., IL-6, IL-8, interferon-ginducible protein 10, monocyte chemoattractant protein-1) in T1D, which may contribute to diabetic nephropathy [68,69 & ], and in particular progressive renal decline [33, 34] . In previous studies, we have also identified urinary biomarker panels for diabetic nephropathy and CAD in patients with T1D in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study [67] .
NOVEL TARGETS FOR THE PREVENTION OF DIABETIC NEPHROPATHY
Inhibition of the RAAS has been the mainstay therapy for the prevention and treatment of diabetic nephropathy. However, the renoprotective role of ACEi/ ARBs has recently been challenged by data from the RASS, which demonstrated that early, primary prevention with ACE inhibition or angiotensin receptor blockade does not modify diabetic nephropathy progression in adults with T1D [18] . Moreover, large clinical trials including Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET), Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE), and Veterans Affairs Diabetes iN Nephropathy Study (VA-NEPHRON-D) have failed to demonstrate improved renal outcomes in diabetic subjects with dual RAAS inhibition using either combined ACEi and ARB or direct renin inhibitor-related regimens [19 && ]. Other classes of agents, including protein kinase C-b antagonists, selective endothelin receptor (A) antagonists, and antioxidants such as bardoxolone, have been associated with disappointing clinical trial results [20, 21] .
There is therefore a need for novel methods of identifying and treating patients at high risk of developing diabetic nephropathy at an early stage to prevent progression. Multiple studies have linked SUA levels to diabetic nephropathy development, and accumulating data have suggested that lowering SUA prevents renal function loss in animal models of diabetes and in patients with type 2 diabetes [24, 70, 71] . To determine the role of SUA lowering in patients with T1D, the multicenter double-blind randomized clinical trial 'Preventing Early Renal Function Loss (PERL)' will test the hypothesis that lowering SUA with allopurinol will prevent GFR decline measured by iohexol [25 && ] (Table 1 ). An additional study design innovation in PERL is the use of GFR (measured by iohexol) as the study end point allowing for the assessment of therapy earlier in the pathophysiologic pathway.
A second potential therapeutic target relates to insulin sensitivity. Reduced insulin sensitivity is well documented in both adolescents and adults with T1D, and is thought to contribute to both the initiation and progression of macrovascular and microvascular complications [72 && ]. We have previously demonstrated that insulin sensitivity predicts the development of microalbuminuria and rapid eGFR decline by cystatin C over six years in patients with T1D [27 & ], similar to data in the Epidemiology of Diabetes Complications study [73] . Various hypotheses exist to explain reduced insulin sensitivity in T1D [74, 75] , but we have shown that only 6% of the variance of insulin sensitivity is explained by SUA in adults with T1D, in contrast to 39% in nondiabetic adults [76 & ]. The absence of a clinically significant association between SUA and reduced insulin sensitivity in T1D may suggest that SUA and reduced insulin sensitivity are independent mediators of vascular pathology in T1D. Despite the findings from the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D) study [77] , which showed no benefit of insulinsensitizing strategy on diabetic nephropathy in patients with type 2 diabetes, modification of insulin sensitivity holds promise as a therapeutic target to reduce vascular complications in T1D, as both lifestyle changes (diet and exercise) and drugs such as metformin can improve insulin sensitivity. The Metformin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) trial was therefore designed to improve insulin sensitivity in T1D (NCT01483560) ( Table 1) .
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors also hold promise as a therapeutic target to prevent progression of diabetic nephropathy in T1D, after it was shown that SGLT-2 inhibition with empagliflozin reduces hemoglobin A1c (HbA1c) and significantly attenuates renal hyperfiltration to near-normal GFR levels in patients with uncomplicated T1D [29 && ] ( Fig. 4) [30] . Patients with T1D exhibited significant weight loss, HbA1c reductions, and a decline in blood pressure [30, [78] [79] [80] . In posthoc analyses of clinical trials, this class of agents acutely reduces eGFR over 3-4 weeks, followed by preservation of renal function over 2 years, and also reduces albuminuria, suggesting a protective decline in intraglomerular pressure [30] , similar to data from GFR inulin studies [29 && ].
Emerging evidence also suggests that acute glycemic excursions may significantly contribute to microvascular end-organ injury in patients with diabetes, independent of long-term glycemic control [81] . Although the mechanisms responsible for end-organ injury with increased glycemic variability are unclear, it has been demonstrated that acute hyperglycemia increases urinary excretion of inflammatory cytokines/chemokines in patients with T1D [68] . Acute hyperglycemia may also contribute to kidney injury via RAAS activation, as it has been demonstrated that acute clamped hyperglycemia activates the RAAS, which subsequently increases the urinary excretion of inflammatory cytokines/chemokines [82 && ]. Furthermore, the increased urinary excretion of inflammatory cytokines/chemokines in response to acute hyperglycemia is blunted by RAAS blockade by direct renin inhibitor in patients with T1D [82 && ]. Arginine vasopressin (AVP) plays an essential role in the regulation of volume status, and exerts important renal and cardiovascular effects. AVP modulates tubular cell growth thereby causing vasoconstriction of the renal microcirculation and in particular in the efferent arteriole [83, 84] . Furthermore, AVP infusion induces hypertension, glomerular hyperfiltration, and albuminuria [85, 86] , and lowering the AVP concentration provides renal protection [87] . There is also evidence linking increased fluid intake with decreased risk for developing CKD [88] . Copeptin is a more stable peptide derived from the same precursor molecule as AVP, and seems to be a useful surrogate marker for AVP in the assessment of fluid and osmosis status in various diseases. Recently, Boertien et al. [31 && ] demonstrated that copeptin predicts the eGFR decline in subjects with type 2 diabetes; however, there is little if any data on its ability to predict diabetic nephropathy in patients with T1D. With the availability of AVP receptor antagonists (e.g., vaptans), AVP might also become a promising therapeutic target for diabetic nephropathy in future.
CONCLUSION
A major challenge in preventing diabetic nephropathy relates to the accurate identification of highrisk patients at an early stage. Identifying risk factors and biomarkers specifically associated with early diabetic nephropathy will help us understand the mechanisms underlying the development and progression of diabetic nephropathy. In this review, we present novel methods of detecting early change in renal function in T1D, and several promising new modifiable targets (insulin sensitivity, SUA, SGLT-2, and copeptin) to slow the progression of early diabetic nephropathy. The translation of these potential methods and therapies into clinical practice now requires investment in adequately powered clinical trials that will capture important renal and cardiovascular long-term outcomes. 
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